Baidu
map

医药分开后,药师去哪儿?

2015-10-27 肖玮 北京商报

药师的工作内容已经发生转变,逐渐担负起监督医生用药、参与会诊以及为患者进行用药咨询等职责。 三年前,医药分开在北京5家公立医院开始试点,药师的新角色曾一度引发热议,甚至被指会彻底沦为卖药人。对此,北京市医管局局长封国生在最新表态中强调,医药分开改革之后,破解药师转型难题确实成为医改必须破解的一大难题,目前,药师的工作内容已经发生转变,逐渐担负起监督医生用药、参与会诊以及为患者进行用药咨询等职

药师的工作内容已经发生转变,逐渐担负起监督医生用药、参与会诊以及为患者进行用药咨询等职责。

三年前,医药分开在北京5家公立医院开始试点,药师的新角色曾一度引发热议,甚至被指会彻底沦为卖药人。对此,北京市医管局局长封国生在最新表态中强调,医药分开改革之后,破解药师转型难题确实成为医改必须破解的一大难题,目前,药师的工作内容已经发生转变,逐渐担负起监督医生用药、参与会诊以及为患者进行用药咨询等职责。业内人士认为,药师的角色变化,也为接下来医院大范围推行医药分开奠定基础,而用药咨询等服务更可能成为新盈利点。

过去在销售药品时,国家允许医院在进价基础上加成15%左右,加成这部分利润留给医院作为对公立医院的补偿。但这种以药养医的模式催生出过度医疗、大处方等行业乱象,也让医药分开成为必然趋势。

近几年来,随着医改不断深入,2010年我国在17个城市启动了公立医院改革试点,2014年试点城市扩大到34个,今年改革试点城市将增加到100个。作为第一批公立医院改革试点城市之一,北京自2012年7月至今,在北京友谊医院、朝阳医院、同仁医院、天坛医院、积水潭医院5家市属医院分三批实施医药分开,取消药品加成、挂号费和诊疗费,设立医事服务费。

业内普遍认为,在医药分开持续推进的过程中,药师转型明显。据北京朝阳医院相关负责人介绍,该医院已推出了处方点评等与医药分开配套的改革举措,医生开的药不合理了,药师可以“打回重审”,药师在处方点评时发现医生开出的大处方等不合理用药,医院会加大对违规医生的处罚力度。

同时,部分医院开始试水药师参与会诊。“目前很多市属医院疑难病例会诊时都要听听临床药师怎么说。医生负责诊断治疗,药师擅长指导用药,会诊的效率效果都得到了提升。”封国生说。

另外,为了更好地指导患者正确服药用药,2014年北京市医院管理局在市属22家医院全部设立用药咨询中心,免费接受患者咨询。患者拿到药后先找用药咨询中心问一问,也逐渐成为患者就医时的新习惯。初步统计,仅2014年22家市属医院用药咨询中心就接待咨询8.8万余例,部分医院最高日咨询量达到近百例。一位医药分析师指出,药师的作用愈发重要,不仅可以让医药分开更加顺畅,且随着患者用药咨询需求越来越大,还有望发展成新的盈利点。

(原文标题:市医管局局长封国生:医药分开改革推动药师转型)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-29 cathymary
  2. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-28 sanshengshi

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-28 梦想天空

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-28 IIIi

    支持!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 Jin Chou

    药师转型还有很多路要走呀

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 sunlong28

    感谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 sunlong28

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 sunlong28

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1408700, encodeId=30de1408e0033, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534900, encodeId=1ae4153490023, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Thu Oct 29 06:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41839, encodeId=947941839e6, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Wed Oct 28 23:44:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41690, encodeId=185841690ee, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:02:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41653, encodeId=4b3f4165350, content=支持!, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Wed Oct 28 07:09:00 CST 2015, time=2015-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41639, encodeId=cf2f416398a, content=药师转型还有很多路要走呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Tue Oct 27 23:23:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41626, encodeId=bc2f416261e, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:42:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41623, encodeId=310f4162364, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41624, encodeId=38a54162417, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41625, encodeId=67ba416256e, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Tue Oct 27 22:41:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 sunlong28

    0

相关资讯

医药股多股登龙虎榜,游资现分歧

鑫富药业(002019.SZ)、嘉应制药(002198.SZ)、鲁抗医药(600789.SH)、千山药机(300216.SZ)等医药股登龙虎榜,其中前两只被游资出货,之后两只被游资出货。 鑫富药业跌停,买五为机构席位,买入46.58万元。卖一为机构席位,卖出500.53万元。卖二为平安证券天津绍兴道证券营业部,卖出289.81万元。该股买卖盘前五名资金净流出,流出资金超649万元; 嘉应制药涨

恒瑞医药耗巨资获欧美认证 海外销售难推广

6月23日晚,恒瑞医药公告,公司生产的注射用奥沙利铂通过美国FDA认证,获准在美国市场销售。据悉,注射用奥沙利铂是恒瑞医药的主力产品之一。但这一看起来利好的消息并未获得市场支持,24日恒瑞医药开盘33.8元,上涨0.03%,报收于33.52元。 据WIND统计,恒瑞医药自2011年以来先后发布了四次公司药品通过欧盟、美国认证的信息,是国内第一家注射液通过美国FDA认证的制药企业。但四次发布信

Science:2014最有意思的十大新闻

最近《Science》杂志推出了2014年最有意思的十个新闻故事,与生物学有关的主要有以下几个: TOP1. 黑死病在人类基因组上留下印迹 大约七百年前,黑死病给欧洲带来了一场毁灭性的灾难,时至今日它的影响还未消失。一项遗传学分析指出,这场灾难改变了欧洲人对一些疾病的应答和对自身免疫疾病的敏感性。 一千年前,吉普赛人(Rroma人)从印度北部迁徙到欧洲,并与遗传背景大为不同的罗马尼亚人通婚。

父爱如山!那些用医药技术帮助孩子的父亲们

父亲节到来,MedSci编辑整理了一些感人的故事,看看强大的父亲们是怎样用医药技术帮助自己患病的孩子的。药企高管研发新药救儿女生物技术公司高管约翰?克罗利(John Crowley)的一儿一女患有庞贝氏症(Pompe disease)。为了救自己的儿女,他与一位科学家合作,成立了一家生物制药公司,研发新药并取得成功。他的故事被写成小说,并被改编成电影《良医妙药》。电影、文学和现实生活中的主人公

医药企业纷纷植入创新元素

近日, 由中国医药工业信息中心评选的2013年度中国医药工业百强榜揭晓。榜单数据显示,主营收入突破100亿元的大型企业数量已增加到11家,较上一届增加两家, 其中排名前两位的广州医药集团有限公司、修正药业集团股份有限公司的主营收入则双双突破400亿元。中小企业也快速成长,主营收入在50亿元~100亿元之间的企业有25家,相比上届增加6家。主营收入50亿元以下有64家,较上届减少8家。与此同时,

Nature :欧洲放宽医药数据共享条例

欧洲药品管理局(EMA)近日宣布,将放宽颇具争议的规则草案以开放临床试验数据,便于公共监督。特别是,该机构表示,出于学术和非商业研究目的,将允许研究人员下载、保存并打印试验数据。之前的草案只允许他们在电脑屏幕上查看数据。 上个月,研究人员和欧盟监察专员猛烈抨击了EMA关于数据共享的政策草案,称其过于有限制性且不切实际。现在,他们对新宣布的政策表示欢迎,但同时警告在定稿中仍存在其他一些有争议的条款

Baidu
map
Baidu
map
Baidu
map